VolitionRx (VNRX) announces that it has signed an agreement with Hologic Diagenode for the co-marketing of Volition’s Nu.Q Discover service. The Nu.Q Discover service provides drug developers and scientists with a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies from discovery to being market ready. Under the agreement, Hologic (HOLX) will co-market Nu.Q Discover services of Volition with Hologic Customers for an initial one-year term. If successful, the aim is for Hologic to be appointed as an exclusive provider of those services, subject to further terms being agreed.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNRX:
- VolitionRX’s Strategic Partnership and Growth Potential Drive Buy Rating
- VolitionRx signs first human out licensing deal for APS
- VolitionRx Ltd. Earnings Call: Key Insights and Challenges
- VolitionRx Reports Q2 2025 Financial Results and Strategic Progress
- VolitionRx reports Q2 revenue $400K, consensus $375.72K